Completed PHASE4 INTERVENTIONAL 3-arm NCT00800462

Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity

Sponsor: Ontario Neurotrauma Foundation

Conditions Neurogenic Detrusor Overactivity Spinal Cord Injury

Interventions Darifenacin Hydrogen Bromide (HBr) Oxybutynin Cl Trospium Cl

Updated 5 times since 2017 Last updated: Apr 4, 2013 Started: Mar 31, 2008 Primary completion: Jun 30, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00800462, this PHASE4 trial focuses on Neurogenic Detrusor Overactivity and Spinal Cord Injury and remains completed. Sponsored by Ontario Neurotrauma Foundation, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ontario Neurotrauma Foundation
Toronto Rehabilitation Institute

Data source: Toronto Rehabilitation Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada
• Winnipeg, Canada